News: Xenon unable to Pass 2b Trials $XENE

Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc., has jointly conducted the placebo-controlled Phase 2b study designed to evaluate the safety and efficacy of topically applied TV-45070 (4% and 8% w/w ointment) in patients with chronic pain due to osteoarthritis (OA) of the knee.

The results were not sufficient to make any difference from placebo in efficacy endpoints of reductions in pain due to OA.

View the full release here.